A Study on Predictors of Treatment Response to daclatasvir and Asunaprevir combination therapy in Patients with genotype 1 Chronic Hepatitis C Virus Infectio
Not Applicable
- Conditions
- Patients with genotype 1 HCV infection
- Registration Number
- JPRN-UMIN000020301
- Lead Sponsor
- Hokkaido University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with poorly controlled cardiac disease (e.g., myocardial infarction, cardiac failure, arrhythmia) 2)Patients with severe hepatic impairment 3)Patients with a history of hypersensitivity to HCV protease inhibitors or NS5A inhibitor 4)Patients with a concurrent malignancy, including hepatocellular carcinoma, at the start of treatment 5)Patients deemed unsuitable for study entry by their treating physician 6)Patients who are unsuitable, in the opinion of the principal investigator, for this study due to any other reason
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate the predictors obtained at baseline and affecting the sustained virologic response (SVR) rate/occurrence of adverse drug reactions at follow-up Week 12
- Secondary Outcome Measures
Name Time Method